|
Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime
Time?
Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation? Apr 16, 2026 Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603 Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time? Apr 16, 2026 Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium Apr 16, 2026 Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 |
Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1-LBA1, June 2026. <br/> 2026-06-10T07:00:00Z NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA100-LBA100, June 2026. <br/> 2026-06-10T07:00:00Z Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1000-LBA1000, June 2026. <br/> 2026-06-10T07:00:00Z Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1003-LBA1003, June 2026. <br/> 2026-06-10T07:00:00Z Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1006-LBA1006, June 2026. <br/> 2026-06-10T07:00:00Z First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1007-LBA1007, June 2026. <br/> 2026-06-10T07:00:00Z A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2). Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1008-LBA1008, June 2026. <br/> 2026-06-10T07:00:00Z Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study). Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA101-LBA101, June 2026. <br/> 2026-06-10T07:00:00Z Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1018-LBA1018, June 2026. <br/> 2026-06-10T07:00:00Z Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA10509-LBA10509, June 2026. <br/> 2026-06-10T07:00:00Z Gabapentin plus tramadol versus tramadol alone for chemoradiotherapy-induced oral mucositis pain in head and neck cancer: Results of a randomized phase III trial. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12001-LBA12001, June 2026. <br/> 2026-06-10T07:00:00Z Ramelteon for prevention of postoperative delirium in elderly cancer patients: A randomized, double-blind, placebo-controlled multicenter trial, JORTC-PON02/J-SUPPORT2103/NCCH2103. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12002-LBA12002, June 2026. <br/> 2026-06-10T07:00:00Z Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12003-LBA12003, June 2026. <br/> 2026-06-10T07:00:00Z SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized controlled trial. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12008-LBA12008, June 2026. <br/> 2026-06-10T07:00:00Z Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1510-LBA1510, June 2026. <br/> 2026-06-10T07:00:00Z SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2-LBA2, June 2026. <br/> 2026-06-10T07:00:00Z |
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. 2026-06-13
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. 2026-06-13
Immunosuppression-Associated Peripheral T-Cell Lymphoma A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate. 2026-06-13
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease The authors report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease. 2026-06-11
Antidotes for Anticoagulation Reversal The authors review current strategies for anticoagulation reversal in major bleeding events or urgent surgery as well as specific antidotes, limits of available evidence, thrombotic risks, unmet therapeutic needs, and ongoing research. 2026-06-11
Osteosarcoma An 11-year-old girl presented with a 1-month history of right thigh pain that worsened at night. Radiographs of the knee revealed a metaphyseal osteoblastic lesion with a sunburst appearance. 2026-06-11
Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing. 2026-06-11
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. 2026-06-10
TRACTION for Greater Surgical Use of Tranexamic Acid Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,... 2026-06-10
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. 2026-06-04
Fasting, Glucocorticoids, and Breast Cancer A study dissects the way in which fasting or a fasting-mimicking diet augments the effect of hormonal therapy in a mouse model of breast cancer. 2026-06-04
Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma In a patient with recurrent ameloblastoma, zolucatetide (formerly FOG-001) produced an ongoing partial response at 40 weeks, with resolution of solid tumor and cerebral edema. Elevated liver-enzyme levels were noted. 2026-06-04
Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used. 2026-06-03
Obexelimab for the Treatment of IgG4-Related Disease In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. 2026-06-02
Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1 2026-06-02
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. 2026-05-31
Perioperative Apalutamide in High-Risk Localized Prostate Cancer In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. 2026-05-31
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. 2026-05-31
A Watershed Moment in the Perioperative Treatment of Prostate Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... 2026-05-31
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. 2026-05-30
|
|
|
| |||
|
[Editorial] The promise and perils of AI in oncology
Technological innovations in health care—including artificial intelligence (AI)—have rapidly transformed core components of oncology care. With public health-care systems under substantial financial strain, advancing digital technology has become a game-changing tool in modern oncology workflows. Such technology offers the potential for more precise, efficient, and cost-effective interventions and could help to revolutionise clinical trials, cancer diagnosis, treatment, and health outcomes; reduce waiting times; and ease pressure on health-care services. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Reshaping breast cancer radiotherapy after FAST-Forward Breast radiotherapy is an integral component of breast cancer care to reduce locoregional recurrence.1 Historically, radiotherapy was delivered daily in 25–30 fractions over 5–6 weeks. Radiobiological and technological advances have enabled hypofractionation: shorter courses with larger doses per fraction achieve similar tumour control while reducing late tissue effects through reduced total dose.2 This approach was established in the first generation breast hypofractionation trials,3,4 in which the 3-week regimen (40 Gy in 15 fractions or 42·5 Gy in 16 fractions) matched the tumour control of conventional fractionation with less late tissue effects. Thu, 14 May 2026 22:30:04 +0000
[Comment] [177Lu]Lu-dota-tate radioligand therapy for advanced pancreatic neuroendocrine tumours Radioligand therapy, commonly referred to as peptide receptor radionuclide therapy (PRRT), is an established and effective treatment for patients with advanced gastroenteropancreatic neuroendocrine tumours who have progressive disease after previous systemic therapy.1 Treatment selection in patients with progressive advanced gastroenteropancreatic neuroendocrine tumours is multifactorial and guided by primary site, hormonal functionality, symptom burden related to tumour volume, extent of metastatic disease, histological grade, and patient preference. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] The global cancer workforce crisis: a shared responsibility, a united front The Lancet Oncology Commission on the cancer workforce1 presents a stark analysis of an impending global health catastrophe. The Commission projects a workforce shortage of nearly 100 million individuals by 2050. This shortage directly correlates with a widening survival gap between high-income countries (HICs) and low-income and middle-income countries (LMICs). By 2050, Africa's 5-year net survival rate could be nearly half that of HICs, a disparity directly linked to the lack of qualified health professionals. Sun, 31 May 2026 12:00:02 +0000
[Comment] Beyond the count: the unseen foundations of cancer care The Lancet Oncology Commission on the cancer workforce1 makes a case that governments, funders, and policy makers can no longer ignore. It elegantly reframes workforce investment—not as a development aspiration but as an economic imperative. However, a compelling case and a complete one are not always the same thing. Sun, 31 May 2026 12:00:02 +0000
[Comment] AI and the cancer workforce: what problem are we solving? The Lancet Oncology Commission on the cancer workforce1 arrives at a moment of mounting pressure on cancer systems worldwide. However, the workforce crisis is not only a question of numbers, it reflects deeper challenges in how care is organised, delivered, and experienced. Patients, families, and caregivers continue to describe systems that are fragmented, impersonal, and poorly equipped to care for the person beyond the disease. At the same time, burnout and moral injury among oncology professionals are rising, further deepening the workforce crisis. Sun, 31 May 2026 12:00:02 +0000
[Comment] From shortage to synergy: transforming global radiology workforce capacity with digital innovation and task-shifting Workforce disparities in cancer care represent one of the most profound and persistent inequities in global health, with low-income and middle-income countries (LMICs) bearing a disproportionate share of cancer mortality. While high-income countries (HIC) maintain a relatively high number of specialists involved in cancer care, many LMICs struggle with major shortages. This inequality is notably severe for diagnostic specialists, who are 15 times more prevalent in HICs than in low-income regions. Sun, 31 May 2026 12:00:02 +0000
[Comment] The UK's radiotherapy workforce shortage: a case for reform The Lancet Oncology Commission on the cancer workforce1 documents a global crisis in the cancer workforce defined by chronic undersupply, accelerating demand, and health systems increasingly unable to recruit and retain the specialists they need. The UK offers a pointed illustration of how domestic policy choices can compound this challenge. Sun, 31 May 2026 12:00:02 +0000
[Comment] Regionally anchored, globally connected: lessons from the Pacific on the cancer workforce crisis The Lancet Oncology Commission on the cancer workforce1 is a timely and important examination of the future unmet need for cancer health professionals, and the devastating fiscal and human cost of inaction. In many settings, this crisis is not looming; it has already arrived. Sun, 31 May 2026 12:00:02 +0000
[Correspondence] Brachytherapy capacity gaps and cancer control priorities Abdurrahman Hajeer and colleagues published findings from an observational study in which 708 948 cancers were estimated to have required brachytherapy across 185 countries in 2022 (3·8% of incident cases).1 Assuming 218 cases per centre annually, 2246 additional centres would be required by 2050. These findings highlight major inequities in access but do not determine priority setting for cancer control resources. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma We read with great interest the OligoPanc consensus by Carl-Stephan Leonhardt and colleagues.1 We congratulate the authors on this landmark interdisciplinary work, which represents the first international effort to standardise the definition of oligometastatic pancreatic ductal adenocarcinoma, and will help harmonise future clinical trials. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma – Authors' reply We thank Hector Prudhomme and colleagues for their interest in our Article describing a consensus definition of oligometastatic pancreatic ductal adenocarcinoma.1 Para-aortic lymph nodes are an important site of metastasis in pancreatic ductal adenocarcinoma and were therefore explicitly addressed, both in the Delphi process and in vignette three. Although 27 (82%) of 33 respondents to vignette three considered it oligometastatic pancreatic ductal adenocarcinoma, only 32 (56%) of 57 in the Delphi consensus classified para-aortic lymph node metastasis as oligometastasis, thereby meaning that the predefined 75% or greater consensus threshold was not reached. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] On the survival benefit from sentinel node biopsy for melanoma We read with interest the systematic review and meta-analysis by Alexander H R Varey and colleagues1 assessing the potential survival benefit of sentinel node biopsy (SNB). We also recognise author John F Thompson for a long and accomplished career that successfully established SNB as a routine part of melanoma diagnostics. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] On the survival benefit from sentinel node biopsy for melanoma – Authors' reply We thank Dirk J Grunhagen and colleagues for their interest in our systematic review. We agree that minimising bias is crucial in such studies. Although individual patient data were not available, the Review was rigorously conducted to minimise residual confounding and selection bias through careful study design and appropriate analyses. Mon, 01 Jun 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 614–24 Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2026; 27: 614–24—In this Article, the third sentence of the last paragraph of the Results section should have read “The most common grade 3–4 adverse events were hypertension (19 [4%] of 445 patients who received darolutamide vs eight [4%] of 221 patients who received placebo), anaemia (14 [3%] vs eight [4%]), and aspartate aminotransferase increase (ten [2%] vs one [<1%]).” This correction has been made to the online version as of June 1, 2026. Mon, 01 Jun 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: e238–47 Widder J, Bol GM, Simek I-M, et al. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium. Lancet Oncol 2026; 27: e238–47—In this Policy Review, the table headings should have read “Frequency”. In the Declaration of interests section, statements have been corrected for Helena M Verkooijen and Luca Visani. These corrections have been made to the online version as of June 1, 2026. Mon, 01 Jun 2026 00:00:00 -0700
[News] Clinicians have no capacity to deliver on England's national cancer plan, think tank warns Clinicians in England do not have the capacity or headspace to do the innovation needed to deliver the Government's National Cancer Plan, a think tank has warned. Thu, 23 Apr 2026 22:30:01 +0000
[News] Air pollution and cancer in Thailand In Thailand, particularly in the northern provinces of the country (eg, Chiang Mai), sustained air pollution, mainly due to persistent wildfires and burning of agricultural waste by farmers, has led to a thick cloud of grey haze and substantial exposure to PM2·5, triggering surges in pollution-related illnesses including cancer. Thu, 30 Apr 2026 22:30:02 +0000
[News] US drinking water polluted with carcinogenic nitrates Almost a fifth of the US population are exposed to potentially cancer-causing nitrates through their drinking water, according to a recent analysis by the Environmental Working Group (EWG). Thu, 30 Apr 2026 22:30:01 +0000
[News] US Senate Bill aims to boost cancer trial enrolment and equity One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushing researchers overseas, where recruitment is often faster and less expensive, while many eligible US Americans—especially older adults, people from racially minoritised or minority ethnic populations, residents of low-income rural communities, and members of Indigenous communities—cannot afford to participate in potentially life-saving trials, largely because of travel expenses. Fri, 08 May 2026 22:30:01 +0000
[News] Radiation oncologists in the USA fight against policy changes On April 27, 2026, US radiation oncologists visited Capitol Hill to tell legislators that the recent policy changes in Medicare have threatened the sustainability of community cancer clinics in the country, as latest data suggested significant economic distress across the field. Thu, 14 May 2026 22:30:04 +0000
[News] ESTRO 2026 David Krug (University Hospital Schleswig-Holstein, Kiel, Germany) presented the first results from a randomised controlled trial showing a progression-free survival benefit from metastasis-directed therapy for patients with oligometastatic breast cancer. In the randomised controlled OLIGOMA trial, patients were randomly assigned to systemic therapy (n=44) or systemic therapy plus stereotactic body radiotherapy (SBRT) to metastatic lesions (n=43). Co-primary endpoints were progression-free survival and quality of life at 12 weeks. Thu, 21 May 2026 22:30:01 +0000
[News] Findings suggest under-reporting of patient data in US SEER Gaps in patient data reported to the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database by some rural, safety-net, and community hospitals could skew cancer rates and survival outcomes in studies of some of the most vulnerable patient populations. Patients treated at facilities not accredited by the American College of Surgeons Commission on Cancer were two to three times more likely to have missing clinical data in SEER patient records than those treated at Commission on Cancer-accredited centres, researchers reported. Thu, 21 May 2026 22:30:00 +0000
[Perspectives] Embedding equity in Germany's National Lung Cancer Screening roll-out: a call to action Lung cancer is the leading cause of cancer deaths, causing approximately 1.8 million deaths worldwide.1 Screening with low-dose CT (LDCT) has been shown to significantly reduce lung cancer-specific mortality among populations at high-risk by 20–26%.2 National lung cancer screening programmes have been implemented in several countries and will be introduced in Germany in 2026. Despite these advances, population-level implementation fails to adequately reach those at highest risk;3 globally, lung cancer screening programmes face persistent challenges in achieving equitable access across racial, ethnic, geographic, and socioeconomic groups. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial Aglatimagene plus valacyclovir was associated with longer disease-free survival than placebo plus valacyclovir when added to standard of radiotherapy for the treatment of localised prostate cancer, offering a meaningful benefit without increasing clinically significant toxicity. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy Long-term follow-up confirms that 26 Gy in five fractions over 1 week is safe and efficacious for adjuvant radiotherapy to the breast or chest wall, supporting its use as a standard of care. Efficacy data for this schedule in the axillary nodal radiotherapy setting are reassuring; however, sample size limits precision of estimation for this subgroup on its own. Thu, 14 May 2026 22:30:02 +0000
[Articles] [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial Using sunitinib as an internal control, our results show clinically significant antitumour efficacy of [177Lu]Lu-dota-tate in pretreated, progressive, somatostatin receptor-positive, metastatic pancreatic neuroendocrine tumours, and a better quality of life during the treatment phase. Late adverse events were reported in the [177Lu]Lu-dota-tate group that might affect the tolerance of subsequent lines of treatment. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher. Sun, 17 May 2026 09:40:01 +0000
[Articles] Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials This pooled analysis from two clinical trials of SABR in patients with larger primary kidney tumours unsuitable for surgery supports evidence of long-term local control and low rate of severe adverse events. These results support further investigation through a randomised trial comparing SABR with surgery in select operable patients. Sun, 17 May 2026 09:40:01 +0000
[Articles] MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised. Thu, 14 May 2026 22:30:02 +0000
[Articles] International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study The pandemic's greatest impact was during the first few months of societal lockdowns in 2020 when barriers in access to health care were greatest. Further research is needed to understand whether patients with a missed diagnosis were diagnosed at a later date and if they presented at a later stage. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice This breast radiotherapy dosimetry audit shows the feasibility of high-quality large-scale, real-world dosimetric collection and evaluation across the NHS in England. Heart and lung doses predominantly met constraints and were comparable to international benchmarks. However, dosimetric variation existed between centres, particularly in volumetric-modulated arc therapy planning, identifying opportunities for quality improvement. Mon, 18 May 2026 15:00:02 +0000
[The Lancet Oncology Commission] Cancer workforce—a global crisis: a Lancet Oncology Commission The shortage of well-trained personnel to deliver cancer care and conduct research remains a major obstacle to reducing disparities in cancer survival between high-income countries and low-income and middle-income countries (LMICs). This Commission set out to provide actionable guidance for strengthening the global cancer workforce with an emphasis on reducing these disparities. To better understand the extent of the rising global cancer burden and the resulting workforce needs, we modelled the current and future global landscape of 17 common cancers and 18 workforce personnel types. Sun, 31 May 2026 12:00:02 +0000
|
Alcohol consumers’ receptivity to artificial intelligence–generated alcohol–cancer risk messages: An experimental study
Artificial intelligence–generated alcohol–cancer messages are feasible and effective in strengthening precursors to behavior change. Cancer‐specific content and higher visual intensity enhance impact, particularly among moderate consumers, highlighting the importance of tailoring alcohol–cancer communication strategies to different audience characteristics. Fri, 12 Jun 2026 04:28:32 -0700 Meeting the moment: Addressing racial disparities in cancer survival Thu, 11 Jun 2026 01:26:21 -0700 Examining bidirectional longitudinal relationships between physical activity and physical function in older breast cancer survivors: The Thinking and Living with Cancer study Higher daily steps predicted better subsequent physical function, especially in survivors. These results highlight the importance of promoting physical activity during cancer survivorship care to maintain functional independence. Wed, 10 Jun 2026 04:25:27 -0700 The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration Tue, 09 Jun 2026 09:55:49 -0700 Breaking barriers: Opt‐out tobacco dependence treatment in oncology care Tue, 09 Jun 2026 09:54:21 -0700 Correction to “Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus‐related liver cirrhosis” Tue, 09 Jun 2026 09:48:23 -0700 Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women Mon, 08 Jun 2026 00:01:03 -0700 Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer Fri, 05 Jun 2026 01:58:14 -0700 Correction to “Clinical, genetic, and familial features of POT1 tumor predisposition syndrome” Fri, 05 Jun 2026 01:48:41 -0700 Site‐ and age‐dependent associations between Fusobacterium nucleatum and colorectal cancer mortality These findings support an association between presence of Fn in CRC tumor tissue and CRC‐specific mortality, particularly for rectal tumors and early‐onset CRC, in a heterogeneous population. Fri, 05 Jun 2026 00:33:48 -0700 Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials In this secondary analysis of the BLC2001 and THOR trials, higher CTCAE hyperphosphatemia grades were associated with improved OS, PFS, and ORR. These findings suggest that hyperphosphatemia may serve as a potential biomarker of erdafitinib activity, and warrant prospective validation. Thu, 04 Jun 2026 04:51:31 -0700 Issue Information Thu, 04 Jun 2026 04:35:32 -0700 |
Genomic Therapy Matching in Rare and Refractory Cancers
This cohort study assesses whether a tiered, evidence-based framework for matching genomic biomarkers to therapies is associated with differential overall survival in patients with advanced solid tumors. Diagnostic Performance of Anti–Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma This multicenter, prospective cohort study assesses the diagnostic performance of anti–Epstein-Barr virus (EBV) BNLF2b in outpatients presenting with suspected nasopharyngeal carcinoma, and compares it with the anti-EBV capsid antigen, anti-EBV early antigen, and anti-EBV nuclear antigen 1 assays. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial This randomized clinical trial evaluates the efficacy and safety of bireociclib plus fulvestrant in hormone receptor–positive, Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer This cohort study validates a novel parsimonious, interpretable, and generalizable model for predicting incident pancreatic ductal adenocarcinoma. Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer This cohort study compares real-world overall survival between sequential and concurrent radiotherapy and immunotherapy among patients with newly diagnosed advanced non–small cell lung cancer. Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial This secondary analysis of a randomized clinical trial explores treatment outcome preferences among older adults with advanced cancer, specifically whether survival or quality of life matters most to the patient. Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis. Survival Without Adjuvant Therapy for Low-Risk Endometrial Cancer With Isolated Tumor Cells This cohort study assesses overall survival without adjuvant therapy in patients with uterine factor–based low-risk endometrial cancer who had isolated tumor cells present in regional lymph nodes. Extensive Oral Ulcerations After Stem Cell Transplant A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems This Viewpoint discusses national systems implementation of cancer medicines included in the WHO Model Lists of Essential Medicines. Obesity Control’s Underestimated Potential for Cancer Prevention This Viewpoint discusses obesity prevention and control as an underestimated and underutilized strategy in the prevention of numerous cancers. Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer—When Policy Delays Care This Viewpoint discusses insurance barriers to next-generation sequencing (NGS) testing for patients with non–small cell lung cancer and proposes policy solutions to address these barriers. The Next Frontier for Transparency in Cancer Randomized Clinical Trials—Data and Safety Monitoring Boards This Viewpoint discusses increasing the transparency in cancer randomized clinical trials through the use of data and safety monitoring boards. JAMA Oncology—TheYear in Review, 2025 Performance of Stereotactic Radiotherapy vs Hippocampal-Avoidance Whole Brain Radiation Delivering Precision Oncology at Scale—Infrastructure, Evidence, and the Path Forward Person-Centered Care in Geriatric Oncology—Understanding What Matters Most Local Consolidative Therapy in Lung Cancer This The Good Cancer, the Barely Cancer, and the Incurable Cancer This essay discusses the author’s reflection on his third cancer diagnosis and how he has lived with cancer throughout his life. The Vocabulary of Survival Possible Biases May Have Limited Study on Ultraprocessed Food Intake Possible Biases May Have Limited Study on Ultraprocessed Food Intake—Reply Error in Tables 2 and 3 JAMA Oncology JAMA Oncology Peer Reviewers in 2025 |
|
|
| |||
|
[Editorial] Closing the sickle cell disease-related health equity gap
June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the WHO recognised sickle cell disease as a global health problem, and although some progress has been made, there is clearly still substantial work to be done to improve outcomes for those living with the disease around the world. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Beyond biomarkers: tissue still matters The diagnosis of primary CNS lymphoma has traditionally relied on stereotactic brain biopsy, while cytological analysis of cerebrospinal fluid (CSF) or vitreous humour is diagnostic in only a minority of patients.1 Although essential for histopathological confirmation, brain biopsy carries inherent risks, with mortality rates ranging from 0·8% to 2·2%, and might cause substantial delays in treatment initiation.1 Consequently, the development of reliable, less invasive diagnostic approaches has become a major objective in the management of primary CNS lymphoma. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Artificial intelligence triage tool for bone marrow fibrosis in myeloproliferative neoplasms using complete blood counts Bone marrow examination is integral to the diagnosis and classification of myeloproliferative neoplasms, but is invasive, can be technically challenging, and is not always immediately feasible. Marie Donzel and colleagues present the Fibrosis Prediction in Bone Marrow using Artificial Intelligence (FIBOM-AI) model,1 a machine learning model trained to predict grade 2–3 bone marrow fibrosis using only age and routine complete blood count (CBC) parameters. Developed from a multicentre cohort using data from 1995 patients with a suspected or established myeloproliferative neoplasm across 13 French centres, and evaluated with both external and prospective validation, this study offers a practical example of how artificial intelligence (AI) can extract insights from routine, inexpensive laboratory data. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Global roadmap for stroke in sickle cell disease: an urgent call to action on an overlooked burden Sickle cell disease is one of the most common severe hereditary disorders worldwide. More than 500 000 infants are born with sickle cell disease each year, the majority in sub-Saharan Africa, where early diagnosis and comprehensive care remain limited.1 Advances in neonatal screening and infection prevention have improved survival, but this success has also exposed the growing lifetime burden of cerebrovascular disease.1 Stroke is a leading cause of morbidity, cognitive impairment, and disability in sickle cell disease. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] A call to embrace qualitative research in haematology journals We write as an international group of qualitative researchers working within haematology. We commend Prasanna Ananth and colleagues for their expert recommendations on conducting and appraising qualitative research, including five pillars that support best practice in qualitative studies.1 Quantitative research can tell us what and how much, but qualitative and mixed methods studies help explain why. These approaches are essential for creating and evaluating interventions that work in real-world contexts. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] The library “Where is Talal?” one of the fellows asked.“Probably in the library” another replied with a chuckle. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] Functional time in chronic lymphocytic leukaemia Chronic lymphocytic leukaemia is often described as indolent—a leukaemia that unfolds slowly, sometimes over decades. In older adults, it behaves less like an acute malignancy and more like a chronic companion. Many patients are diagnosed incidentally and require no immediate therapy. The biology might be calm but the lived experience rarely is. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] Ayako Arai: 25 years dedicated to a rare but devastating condition When Ayako Arai was at medical school in the late 1980s, she became fascinated with the “extraordinary beauty” of blood cells under a microscope. At the time, haematopoietic stem-cell transplantation (HSCT) was just becoming established and the concept of molecular targeted therapy beginning to emerge. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] You Look Fine “You Look Fine” begins with LA-based comedian Jared “J” Snow trying a bit of boxing. His trainer holds the mitts and calls the combinations. Jab, right, hook, right, roll, finish with another right. J lands punches, moves competently around the ring, and rests when the bell sounds. After three rounds, he starts feeling discomfort in his chest, so he stops training and goes home to bathe in Epsom salts and swallow some painkillers. He hopes this will be enough to forestall a sickle cell crisis. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial Adverse events were few, probably due to organ sparing by total marrow and lymphoid irradiation. Total marrow and lymphoid irradiation 2000 cGy could be safely delivered in combination with high-dose etoposide and cyclophosphamide. The regimen was associated with encouraging 2-year progression-free survival rates. Mon, 18 May 2026 22:30:02 +0000
[Articles] Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study In this prospective, multicentre cohort of patients with suspected primary CNS lymphoma, we validated the high diagnostic value of MYD88, IL-10, and CXCL13. Results should be interpreted within the full clinical context and with caution, as the diagnostic algorithm and decision tree were derived within the same cohort. In selected clinical scenarios and with further validation of these results, combined CSF biomarker testing might support non-invasive diagnostic decision making and reduce reliance on brain biopsy. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Post pulmonary embolism syndrome following paediatric pulmonary embolism: a multicentre, retrospective cohort study This study showed a high prevalence of post pulmonary embolism syndrome in children with pulmonary embolism. Different clinical factors can contribute, including psychological distress factors and physical limitations, emphasising the need for comprehensive, multidisciplinary care. Wed, 20 May 2026 22:30:01 +0000
[Articles] Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study FIBOM-AI can be reliably used as a triage and prioritisation tool to support timely bone marrow evaluation or provide complementary risk assessment when bone marrow biopsy is not immediately feasible. Mon, 01 Jun 2026 00:00:00 -0700
[Review] Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and Australia worked together on behalf of the EBMT Practice Harmonisation and Guidelines Committee to delineate a pragmatic diagnostic framework and issue guidance for downstream clinical management for DDHN. The team met on Sept 18–19, 2025, in Berlin, Germany, to discuss the definition, molecular insights, treatments, and donor outcomes for DDHN after an intensive review of the literature. Mon, 01 Jun 2026 00:00:00 -0700
[Review] A novel US-based grading system for disease severity in sickle cell disease: the Sickle Cell Outcome Grading System (SCOGS) Sickle cell disease is a haematological disorder marked by recurrent events and progressive organ dysfunction, yet a standardised framework to assess disease severity is lacking. We developed a novel US-based severity grading system through identification of sickle cell disease-related complications mapping all to the Common Terminology Criteria For Adverse Events and applying a five-level severity scale. A modified Delphi process involving 29 US-based sickle cell disease experts was conducted over three virtual rounds (from Oct 20 to Nov 8, 2023; from June 26 to Aug 1, 2024; and from Nov 6, 2024, to Jan 7, 2025), with the use of a 9-point Likert scale ratings and iterative feedback. Mon, 01 Jun 2026 00:00:00 -0700
[Clinical Picture] Double trouble: sequential lymphomas An 83-year-old woman presented to our haematology department in June, 2025, with a 3-month history of palpable cervical lymphadenopathy and splenomegaly. Contrast-enhanced CT revealed enlarged cervical, axillary, inguinal, and visceral lymphadenopathy. A biopsy of a cervical lymph node verified a diagnosis of stage IV angioimmunoblastic T-cell lymphoma (AITL; appendix pp 3–4). Immunohistochemistry showed atypical T cells positive for CD3, CD4, CD10, CD30, ICOS, BCL6, and PD1. In-situ hybridisation for Epstein–Barr virus (EBV)-encoded RNA (EBER) testing was negative (appendix p 7). Mon, 01 Jun 2026 00:00:00 -0700
|
MYB builds leukemic enhancers
Volume 147, Issue 24 June 11 2026 Minimal residual disease in CLL: when does it really matter? Volume 147, Issue 24 June 11 2026 Bone marrow endothelial injury by venetoclax and azacitidine Volume 147, Issue 24 June 11 2026 How does NSD2 fuel multiple myeloma? Volume 147, Issue 24 June 11 2026 Hitting AML where it breathes: the peroxisome fat trap Volume 147, Issue 24 June 11 2026 The inflammatory “death-to-life” loop in VEXAS syndrome Volume 147, Issue 24 June 11 2026 A step towards guided complement-targeted therapy in ITP? Volume 147, Issue 24 June 11 2026 Bridging the gap to pregnancy for modeling FNAIT prophylaxis Volume 147, Issue 24 June 11 2026 Magnificent Seven? CD7 CARTs take a surprise shot at AML Volume 147, Issue 24 June 11 2026 MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia How transcription factors (TFs) simultaneously activate enhancers and connect them to their target genes has remained a central question in leukemia biology. In this Plenary Paper, Lau and colleagues tackle this question in KMT2A-rearranged acute lymphoblastic leukemia. The authors demonstrate that binding of MYB, a key hematopoietic TF, is sufficient to drive novel enhancer activation, including initiating 3D contact with target promoters to drive ectopic expression of distal oncogenes. Continued MYB binding is required to maintain enhancer-promoter interactions, indicating that disruption of MYB is therapeutically tractable in multiple leukemias.
Volume 147, Issue 24 June 11 2026 From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma When breakthrough therapies arrive in a stubbornly stable disease area, they inevitably shake up patterns of care for the better. Kamdar and Bartlett review this welcome phenomenon in relapsed and refractory large B-cell lymphoma, where the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. With these new tools comes the challenge of how to efficiently transform treatment paradigms in a timely and evidence-based manner, and this review provides the field with salient guidance for achieving this.
Volume 147, Issue 24 June 11 2026 Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial The disease course of chronic lymphocytic leukemia (CLL) is heterogeneous but typically is long, and traditional end points for trials such as progression-free survival and overall survival are increasingly unrealistic for drug development when most patients do well. Sharman et al report on the results of the first randomized study of treatment-naive CLL that used undetectable minimal residual disease as the sole primary end point, proving the superiority of venetoclax plus obinutuzumab (VenO) over older standard chemoimmunotherapy regimens by 15 months with this surrogate end point. Longer follow-up could well validate this end point for first-line treatments in future registration trials.
Volume 147, Issue 24 June 11 2026 Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage Prolonged cytopenias after chemotherapy-based induction therapy for acute myeloid leukemia is brought about by hematopoietic stem cell toxicity and damage to the bone marrow (BM) microenvironment. But what about induction with venetoclax-azacitidine? Ngo and colleagues used in vivo models to identify selective injury to sinusoidal endothelial cells caused by venetoclax-azacitidine, revealing a therapy-associated mechanism that links BM niche damage to impaired hematopoietic recovery. These data help explain the prolonged BM hypoplasia observed in some patients and prompt further research into how other targeted therapy-based induction regimens influence the BM microenvironment.
Volume 147, Issue 24 June 11 2026 Study of NSD2 using a dTAG system reveals its molecular mechanism and oncogenic implications in t(4;14) multiple myeloma Volume 147, Issue 24 June 11 2026 Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells Volume 147, Issue 24 June 11 2026 Inflammatory cell death and monocyte dysfunction in VEXAS syndrome VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene. Using primary cells and cell lines, Breillat et al reveal hypersensitivity to tumor necrosis factor–driven cell death and impaired innate immune response underpinning the disease, thereby explaining the dual phenomena of increased inflammation and susceptibility to infection.
Volume 147, Issue 24 June 11 2026 Complement activation profile in adult primary immune thrombocytopenia Immune thrombocytopenia (ITP) is clinically heterogeneous, reflecting differing etiologies of immune dysregulation. Nakata et al provide important biological insights by examining complement deposition directly on the surface of washed platelets, identifying patients with either no, minimal, or strong complement activation, and demonstrating at least partial association with detection of immunoglobulin G or immunoglobulin M antiplatelet antibodies. The authors’ work explains the mixed results for complement inhibitor therapy in ITP to date and may facilitate selection of patients most likely to respond to these agents.
Volume 147, Issue 24 June 11 2026 Transfusing HPA-mismatched platelets to mimic fetomaternal hemorrhage elicits fetal/neonatal alloimmune thrombocytopenia Volume 147, Issue 24 June 11 2026 Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia Developing effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has proven challenging. In this preliminary report, Becilli and colleagues demonstrate the efficacy and safety of autologous CD7-directed CAR T cells lacking CD7 expression in 3 young patients with poor prognosis, relapsed CD7-expressing AML, with clearance of measurable residual disease and documentation of reconstitution of CD7-negative natural killer cells and T cells in all. For patients with CD7-expressing AML, this approach may be an attractive bridging option to allogeneic stem cell transplantation.
Volume 147, Issue 24 June 11 2026 Acquisition of Philadelphia chromosome at relapse in a case of Ph-like B-ALL Volume 147, Issue 24 June 11 2026 Ellis L, Bots M, Lindemann RK, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood. 2009;114(2):380-393. Volume 147, Issue 24 June 11 2026 Grabow S, Delbridge ARD, Valente LJ, Strasser A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood. 2014;124(26):3939-3946. Volume 147, Issue 24 June 11 2026 |
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Mon, 08 Jun 2026 22:11:25 -0700 Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia Sun, 07 Jun 2026 22:46:19 -0700 Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”? Sun, 07 Jun 2026 22:03:34 -0700 Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma Sun, 07 Jun 2026 22:01:35 -0700 Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents Sun, 07 Jun 2026 20:56:40 -0700 Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis Sun, 07 Jun 2026 20:54:57 -0700 Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta‐Analysis of CAR T‐Cell Therapy for Hematologic Malignancies Fri, 05 Jun 2026 02:46:16 -0700 Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice Thu, 04 Jun 2026 03:57:44 -0700 Development and Validation of a Novel Conditional Event‐Free Survival Tool in Diffuse Large B‐Cell Lymphoma Thu, 04 Jun 2026 03:43:02 -0700 Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia Wed, 03 Jun 2026 21:37:28 -0700 Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0 Wed, 03 Jun 2026 21:36:15 -0700 Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study Wed, 03 Jun 2026 21:11:15 -0700 JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis Tue, 02 Jun 2026 02:00:43 -0700 Compound Heterozygosity for Hemoglobin S and Hemoglobin LuLu Island Tue, 02 Jun 2026 00:47:02 -0700 Somatic Mutations in Acquired Pure Red Cell Aplasia: Incidence and Implications Tue, 02 Jun 2026 00:47:02 -0700 Issue Information Tue, 02 Jun 2026 00:47:02 -0700 Correction to “Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin (EPO) Due to EPO c.‐136 G>A Germline Mutation” Tue, 02 Jun 2026 00:47:02 -0700 Natural History of Chronic Kidney Disease in Sickle Cell Disease Tue, 02 Jun 2026 00:47:02 -0700 Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision‐Making Tue, 02 Jun 2026 00:47:02 -0700 Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights Tue, 02 Jun 2026 00:47:02 -0700 The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors Tue, 02 Jun 2026 00:47:02 -0700 |
|
|
| |||
|
Popping FVIII concentrates into an updated classification May 26 2026 - Volume 10, Issue 10 On the RAdR in relapsed T-cell lymphoma May 26 2026 - Volume 10, Issue 10 CD19 CAR T cells for B-ALL with EMD May 26 2026 - Volume 10, Issue 10 Platelets pull: how thrombin drives contractility May 26 2026 - Volume 10, Issue 10 Six-year FIX-padua gene therapy in hemophilia B May 26 2026 - Volume 10, Issue 10 Yes, we can omit TBI for ALL! May 26 2026 - Volume 10, Issue 10 Progress over perfection: evolving treatments in LCH May 26 2026 - Volume 10, Issue 10 Chewing the fat: the role of total cholesterol in MPN management May 26 2026 - Volume 10, Issue 10 Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective May 26 2026 - Volume 10, Issue 10 Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners May 26 2026 - Volume 10, Issue 10 Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia May 26 2026 - Volume 10, Issue 10 Selinexor plus ruxolitinib in JAK inhibitor–naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study May 26 2026 - Volume 10, Issue 10 A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma May 26 2026 - Volume 10, Issue 10 Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia May 26 2026 - Volume 10, Issue 10 Low flow cytometry events in detecting CNS involvement in pediatric B-cell precursor ALL: NGS validation and prognostic significance May 26 2026 - Volume 10, Issue 10 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B May 26 2026 - Volume 10, Issue 10 Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis May 26 2026 - Volume 10, Issue 10 Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study May 26 2026 - Volume 10, Issue 10 Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study May 26 2026 - Volume 10, Issue 10 Burnout in sickle cell disease–focused hematology-oncology–trained physicians: a national cross-sectional study May 26 2026 - Volume 10, Issue 10 Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study May 26 2026 - Volume 10, Issue 10 Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS May 26 2026 - Volume 10, Issue 10 CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review May 26 2026 - Volume 10, Issue 10 Digenic and multigenic heterozygous FHL genotypes are common but clinically silent in the general population May 26 2026 - Volume 10, Issue 10 Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma May 26 2026 - Volume 10, Issue 10 Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL May 26 2026 - Volume 10, Issue 10 Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma May 26 2026 - Volume 10, Issue 10 Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study May 26 2026 - Volume 10, Issue 10 Proteogenomic features define subtypes of mantle cell lymphoma May 26 2026 - Volume 10, Issue 10 Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines May 26 2026 - Volume 10, Issue 10 Validation of ICC hierarchical classification in secondary AML May 26 2026 - Volume 10, Issue 10 IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation May 26 2026 - Volume 10, Issue 10 Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients May 26 2026 - Volume 10, Issue 10 Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms May 26 2026 - Volume 10, Issue 10 Regulation of platelet contractility by agonists present across a thrombus May 26 2026 - Volume 10, Issue 10 Plasma proteome signatures are predictive of mortality in sickle cell disease May 26 2026 - Volume 10, Issue 10 Multiomics analysis of red blood cells reveals thalassemia severity beyond globin gene mutations May 26 2026 - Volume 10, Issue 10 A revised classification of FVIII concentrates: rationale and novel metrics May 26 2026 - Volume 10, Issue 10 Rat models of thrombotic thrombocytopenic purpura reveal crucial role of placental ADAMTS13 in perinatal survival May 26 2026 - Volume 10, Issue 10 Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders May 26 2026 - Volume 10, Issue 10 Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation May 26 2026 - Volume 10, Issue 10 BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease May 26 2026 - Volume 10, Issue 10 Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome May 26 2026 - Volume 10, Issue 10 Structure of factor VII Gla domain bound to EPCR May 26 2026 - Volume 10, Issue 10 Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes May 26 2026 - Volume 10, Issue 10 Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma May 26 2026 - Volume 10, Issue 10 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease
New England Journal of Medicine, Volume 394, Issue 22, Page 2212-2222, June 11, 2026.
IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease New England Journal of Medicine, Volume 394, Issue 22, Page 2189-2199, June 11, 2026.
Intravascular Ultrasound–Guided or Angiography-Guided Complex High-Risk PCI New England Journal of Medicine, Volume 394, Issue 22, Page 2200-2211, June 11, 2026.
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism New England Journal of Medicine, Volume 394, Issue 22, Page 2276-2279, June 11, 2026.
Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus New England Journal of Medicine, Volume 394, Issue 22, Page 2274-2276, June 11, 2026.
Seeing the Left Main Coronary Artery Clearly — Is IVUS Always Necessary? New England Journal of Medicine, Volume 394, Issue 22, Page 2266-2268, June 11, 2026.
Osteosarcoma New England Journal of Medicine, Volume 394, Issue 22, Page 2255-2255, June 11, 2026.
Case 16-2026: A 14-Year-Old Girl with Hypertension New England Journal of Medicine, Volume 394, Issue 22, Page 2256-2264, June 11, 2026.
Carrier New England Journal of Medicine, Volume 394, Issue 22, Page 2185-2187, June 11, 2026.
Detecting Gambling-Related Problems — An Opportunity to Reduce Suicidality New England Journal of Medicine, Volume 394, Issue 22, Page 2180-2182, June 11, 2026.
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease New England Journal of Medicine, Ahead of Print.
Angiography-Derived Fractional Flow Reserve to Guide PCI New England Journal of Medicine, Ahead of Print.
Angiography-Based Physiology to Guide Coronary Revascularization New England Journal of Medicine, Ahead of Print.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage New England Journal of Medicine, Ahead of Print.
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer New England Journal of Medicine, Ahead of Print.
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer New England Journal of Medicine, Ahead of Print.
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer New England Journal of Medicine, Ahead of Print.
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica New England Journal of Medicine, Ahead of Print.
Finerenone in Persons with Chronic Kidney Disease without Diabetes New England Journal of Medicine, Ahead of Print.
Survodutide Once Weekly for the Treatment of Adults with Obesity New England Journal of Medicine, Ahead of Print.
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery New England Journal of Medicine, Ahead of Print.
Carbocisteine or Hypertonic Saline for Acute Respiratory Failure New England Journal of Medicine, Ahead of Print.
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema New England Journal of Medicine, Ahead of Print.
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection New England Journal of Medicine, Ahead of Print.
Andes Hantavirus Outbreak on a Cruise Ship, 2026 New England Journal of Medicine, Ahead of Print.
Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
Stenting for Post-Thrombotic Syndrome — A Step Forward New England Journal of Medicine, Ahead of Print.
Precision Intensification in Metastatic Prostate Cancer New England Journal of Medicine, Ahead of Print.
Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
|
Digital Therapeutics for Fecal Incontinence: What Real-World Data Can Support, and What It Cannot Diseases of the Colon & Rectum.69(6):1663-1665, June 2026. Reinterpreting Outcomes Following Different Neoadjuvant Treatment Approaches for Locally Advanced Rectal Cancer: Perspectives of the Discerning Reader Diseases of the Colon & Rectum.69(6):1666-1670, June 2026. Rupert B. Turnbull Jr, M.D., and Norma N. Gill: Founders of Enterostomal Therapy Diseases of the Colon & Rectum.69(6):1671-1678, June 2026. Rethinking Intestinal Stem Cells: Why Fgfbp1+ Progenitors Might Be More Critical Than the Lgr5+ Population Diseases of the Colon & Rectum.69(6):1679-1681, June 2026. Ulcerative Colitis-Associated Neoplasia Diseases of the Colon & Rectum.69(6):1682-1686, June 2026. Expert Commentary on Ulcerative Colitis–Associated Neoplasia Diseases of the Colon & Rectum.69(6):1687, June 2026. Textbook Outcome After IPAA for Ulcerative Colitis: A Nationwide Multicenter Study and Its Implications for Long-term Quality of Life Diseases of the Colon & Rectum.69(6):1688-1696, June 2026. Short-term Surgical Outcomes After Transanal Restorative Proctocolectomy With IPAA: A Comparison of Close Rectal Dissection and Modified Total Mesorectal Excision Diseases of the Colon & Rectum.69(6):1697-1701, June 2026. Tumor Necrosis Factor Alpha Inhibitors Reduce Staged Surgery Rate and Prevent Postoperative Endoscopic Recurrence in Patients With Crohn’s Disease Diseases of the Colon & Rectum.69(6):1702-1711, June 2026. A Digital Therapeutic Pelvic Health System Improves Fecal Incontinence Symptoms in a Real-World Patient Cohort Diseases of the Colon & Rectum.69(6):1712-1721, June 2026. Clinician and Patient Stakeholders Prioritize Rectal Prolapse Research Themes Through an International Delphi Process Diseases of the Colon & Rectum.69(6):1722-1731, June 2026. “Nobody Told Me”: A Qualitative Study of Sexual and Reproductive Concerns After Treatment for Early-Onset Colorectal Cancer Diseases of the Colon & Rectum.69(6):1732-1740, June 2026. Urinary Function After Laparoscopic Surgery in Very Low Rectal Cancer Diseases of the Colon & Rectum.69(6):1741-1748, June 2026. Influence of Circular Stapler Size and Number of Linear Stapler Firings on Anastomotic Leakage in Colorectal Surgery: A Retrospective Analysis of 1491 Patients Diseases of the Colon & Rectum.69(6):1749-1755, June 2026. Financial Toxicity Following Locally Advanced Rectal Cancer Treatment Diseases of the Colon & Rectum.69(6):1756-1765, June 2026. A Critical Appraisal of Colorectal Surgery Fellowship Standardized Letters of Recommendations Using Objective Criteria Diseases of the Colon & Rectum.69(6):1766-1771, June 2026. Selected Abstracts Diseases of the Colon & Rectum.69(6):1772-1776, June 2026. Robotic Splenic Flexure Colectomy With End-To-End Handsewn Anastomosis Diseases of the Colon & Rectum.69(6):1777, June 2026. Robotic-Assisted Reversal of Hartmann’s Procedure With Retroileal Tunnel of the Transverse Colon Diseases of the Colon & Rectum.69(6):1778, June 2026. Robotic Extended Left Colectomy With Colorectal Anastomosis Via Retroileal Window Diseases of the Colon & Rectum.69(6):1779-1780, June 2026. |
||
|
| |||
|
New Research Links Low Alcohol Consumption to Elevated Health Risks
Researchers reported there was no protective net effect of any level of alcohol consumption on health observed in a new study published by George et al in the Journal of Studies on Alcohol and Drugs. Further, researchers reported that low levels of alcohol use may be associated with elevated health ... Tuesday, June 9, 2026 10:15 AM Digital Tool May Improve Patient Engagement in Oncology Clinical Trials In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP). Alliance created PEP to... Tuesday, June 9, 2026 10:30 AM GLP-1 RAs May Reduce Risk of Obesity-Related Cancers Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a 41% lower risk of developing obesity-associated cancers in the short term for obese, nondiabetic patients, according to findings from an observational study published in Annals of Oncology. Tuesday, June 9, 2026 10:00 AM Teclistamab in Previously Treated Multiple Myeloma As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Touzeau et al, an interim analysis of the phase III MajesTEC-9 trial has shown improved progression-free survival with teclistamab vs investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd)... Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Agarwal et al, the phase III TALAPRO-3 trial has shown improved imaging-based progression-free survival with the addition of talazoparib to enzalutamide in patients receiving androgen-deprivation therapy for... Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma... Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Zhou et al, the phase III WU-KONG28 trial has shown that first-line sunvozertinib improved progression-free survival vs chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC)... FDA Approves Durvalumab Plus BCG for High-Risk NMIBC On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). Thursday, May 28, 2026 2:18 PM FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA... Friday, May 15, 2026 2:22 PM Which Genes Contribute to Early-Onset Breast Cancer in Black Women? Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer. New research published by Beasley et al in Cancer reveals the genes that are most likely to be mutated to contribute to these increased risks. Monday, June 8, 2026 10:40 AM AML: All-Oral Regimen Safe and Eases Treatment Administration Burden An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine. Friday, June 5, 2026 1:30 PM Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers. Friday, June 5, 2026 10:43 AM Overall Survival With EBRT in Hepatocellular Carcinoma In an individual patient analysis reported in the Journal of Clinical Oncology, Moon et al found that treatment of early-stage hepatocellular carcinoma (HCC) with external-beam radiation therapy (EBRT) was associated with survival outcomes comparable to other treatment modalities such as surgical... SCLC With Brain-Only Progression: Original or Substitute Systemic Therapy With or Without Brain Radiotherapy In a Chinese retrospective cohort study reported in the Journal of Clinical Oncology, Lu et al found that adding brain radiotherapy to continued original systemic therapy produced better outcomes compared to brain radiotherapy and substitution of systemic therapy or substitution of systemic therapy ... Five-Year Survival Analysis: Neoadjuvant Trastuzumab/Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers are diagnosed, reducing the burden of stage IV cancers. However, the study did not achieve its... Tuesday, June 2, 2026 11:09 AM GLP-1 RAs May Be Associated With Lower Breast Cancer Incidence Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506). The findings were also published in JCO Oncology Practice. Thursday, June 4, 2026 12:30 PM American Cancer Society Updates Colorectal Cancer Screening Guideline The American Cancer Society (ACS) recently released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 years and continue through age 75 years for those with a life expectancy greater than... Thursday, June 4, 2026 11:24 AM Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma In an analysis reported in The Lancet, Dreyling et al provided long-term findings with three first-line regimens in the phase III TRIANGLE trial among patients aged 18 to 65 years with mantle cell lymphoma. Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response? A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580). Thursday, June 4, 2026 11:01 AM Online Patient Resources About AI and Cancer Found Lacking Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages... Wednesday, June 3, 2026 1:00 PM Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared with pembrolizumab alone in patients with high-risk resected melanoma, according to 5-year results... Wednesday, June 3, 2026 1:00 PM Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO... Wednesday, June 3, 2026 1:00 PM Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory... Wednesday, June 3, 2026 10:52 AM Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with a family history of breast cancer will ultimately develop the disease (Abstract 10545). Although... Wednesday, June 3, 2026 10:41 AM Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recurrent endometrial cancer, according to findings presented during the Gynecologic Oncology Session at ... Wednesday, June 3, 2026 10:24 AM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia
Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Fri, 12 Jun 2026 00:00:00 -0700 Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma Fri, 12 Jun 2026 00:00:00 -0700 Adjuvant selpercatinib shows benefit in patients with NSCLC Adjuvant selpercatinib shows benefit in patients with NSCLC Thu, 11 Jun 2026 00:00:00 -0700 Ivonescimab improves overall survival Ivonescimab improves overall survival Thu, 11 Jun 2026 00:00:00 -0700 From ASCO 2026 From ASCO 2026 Thu, 11 Jun 2026 00:00:00 -0700 Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement Despite considerable improvements in the outcomes in patients with hepatocellular carcinoma (HCC), many outstanding research questions remain unanswered. Furthermore, significant findings from successful phase III trials have not always been translated into guideline-recommended therapies, implying a need for improved standardization of trial end points. In this Consensus Statement, representatives of four major societies (the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO)) convened to provide guidance on end point selection for clinical trials conducted in various settings including surveillance, and early-stage, intermediate-stage and advanced-stage HCC. Wed, 10 Jun 2026 00:00:00 -0700 The future is not always uniform: rethinking radiotherapy through spatial fractionation Traditional radiotherapy approaches involve the delivery of a uniform radiation dose to the entire tumour. Despite considerable effectiveness, this approach comes with the limitations of a lack of activity against larger tumour volumes as well as off-target irradiation of surrounding non-malignant tissues. Spatially fractionated radiotherapy, involving deliberate non-uniform irradiation, has the potential to address these challenges, with early data suggesting safety and activity in patients with advanced-stage cancers. In this Review, the authors describe the emerging role of spatially fractionated radiotherapy in the management of patients with cancer. Wed, 10 Jun 2026 00:00:00 -0700 RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets Recent data from the RECITE trial indicating that the thrombopoietin receptor agonist romiplostim ameliorates chemotherapy-induced thrombocytopenia offer hope for the first drug treatment for this condition. However, the ultimate goal is not to improve platelet counts but patient outcomes, and RECITE does not offer evidence of survival or quality-of-life benefits that truly matter to patients. Tue, 09 Jun 2026 00:00:00 -0700 |
|
|
| |||
|
Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer
Vol 17, No 2 (April 30, 2026): Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study Vol 17, No 2 (April 30, 2026): The prevalence of gastric intestinal metaplasia in the Saudi population: a single-tertiary center retrospective study Vol 17, No 2 (April 30, 2026): Prognostic impact of low absolute skeletal muscle mass 6 months after gastrectomy for gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Diagnostic value of mini-probe endoscopic ultrasound in preoperative tumor nodal (TN) staging of gastric cancer and analysis of factors influencing T-staging accuracy Vol 17, No 2 (April 30, 2026): Transcatheter arterial embolization with N-butyl cyanoacrylate versus gelatin sponge particles for gastric cancer-related upper gastrointestinal bleeding: a comparison of efficacy and safety Vol 17, No 2 (April 30, 2026): Postoperative frailty among elderly patients undergoing radical surgery for gastrointestinal tumors and its relationship with prognosis Vol 17, No 2 (April 30, 2026): Molecular characteristics and metastatic mechanism of patients diagnosed with Krukenberg tumor from gastric cancer Vol 17, No 2 (April 30, 2026): Retrospective study on clinical outcomes and safety evaluation of da Vinci robot-assisted laparoscopy and endoscopic cooperative for small gastric stromal tumors resection: preliminary single-center experience Vol 17, No 2 (April 30, 2026): The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis Vol 17, No 2 (April 30, 2026): Comparison of the efficacy and safety of single-incision versus multi-port laparoscopic D2 lymphadenectomy for locally advanced gastric cancer: a systematic review and meta-analysis Vol 17, No 2 (April 30, 2026): Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer Vol 17, No 2 (April 30, 2026): Identification of immunogenic cell death-related prognostic genes in gastric cancer Vol 17, No 2 (April 30, 2026): Opportunistic CT screening for osteosarcopenia predicts reduced overall survival in patients with gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer Vol 17, No 2 (April 30, 2026): Identification of an autophagy-related prognostic signature and validation of WDR45 in colorectal cancer Vol 17, No 2 (April 30, 2026): KRAS mutation subtypes refine prognostic stratification in colorectal cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of manganese metabolism-related genes prognostic model in colorectal cancer and its immunological characteristics Vol 17, No 2 (April 30, 2026): Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II–III colorectal cancer Vol 17, No 2 (April 30, 2026): Assessment of colorectal cancer recurrence risk following solid organ transplantation Vol 17, No 2 (April 30, 2026): CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1 Vol 17, No 2 (April 30, 2026): Molecular subtyping and prognostic model construction based on endosome-related genes in colorectal cancer Vol 17, No 2 (April 30, 2026): No survival benefit from adjuvant chemotherapy in high-risk stage II small intestinal adenocarcinoma after surgery: a population-based long-term survival analysis Vol 17, No 2 (April 30, 2026): Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience Vol 17, No 2 (April 30, 2026): Single-cell transcriptome analysis identifies neutrophil-related prognostic signatures in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): TRNP1 regulates tumorigenesis and enhances immunotherapy response via c-Kit/STAT3 signaling in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Perioperative clinicopathologic model for predicting 12-month early recurrence after curative hepatectomy in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Association of serum lactate dehydrogenase levels with the severity of microvascular invasion in hepatocellular carcinoma: a retrospective cross-sectional study Vol 17, No 2 (April 30, 2026): An exploratory nomogram model with 18F-FDG PET/CT metabolic parameters for predicting high-risk status of microvascular invasion in hepatocellular carcinoma patients prior to liver transplantation Vol 17, No 2 (April 30, 2026): Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs Vol 17, No 2 (April 30, 2026): Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing Vol 17, No 2 (April 30, 2026): PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of a model for predicting short-term complications after hepatectomy in patients with primary liver cancer Vol 17, No 2 (April 30, 2026): Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): A novel deep learning and radiomics approach based on DCE-MRI for predicting the P53 mutation status in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Peripheral regulatory T cells trajectory predicts progression-free survival in hepatocellular carcinoma patients during on-demand transarterial chemoembolization using joint model: a prospective study Vol 17, No 2 (April 30, 2026): PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study Vol 17, No 2 (April 30, 2026): Indeterminate nodule-like arterial phase hyperenhancement in the liver on CT: differentiation of hepatocellular carcinomas from vascular pseudolesions using a CT radiomics approach Vol 17, No 2 (April 30, 2026): Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database Vol 17, No 2 (April 30, 2026): Multi-scale deep learning models based on MRI for predicting pathological differentiation and evaluating its association with recurrence-free survival in hepatocellular carcinoma: an explainable machine learning study Vol 17, No 2 (April 30, 2026): Daily increment of residual liver regeneration (DIRER) predicts tumor recurrence and mortality after radical hepatectomy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Silencing OTUB1 induces pyroptosis to inhibit the growth of liver cancer HepG2 cells via the NLRP3/caspase/GSDM signaling pathway Vol 17, No 2 (April 30, 2026): Targeting AKR1C1 overcomes lenvatinib resistance in hepatocellular carcinoma through the STAT3-ABC transporters pathway Vol 17, No 2 (April 30, 2026): Multi-institutional care is associated with improved survival in biliary tract cancer Vol 17, No 2 (April 30, 2026): Development and validation of machine learning models integrating spectral computed tomography-derived three-dimensional quantitative parameters for predicting histopathological grade in pancreatic ductal adenocarcinoma Vol 17, No 2 (April 30, 2026): A biomarker-integrated nomogram for predicting postoperative pancreatic fistula in low- to intermediate-risk patients after pancreaticoduodenectomy Vol 17, No 2 (April 30, 2026): Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study Vol 17, No 2 (April 30, 2026): A TRPM4-associated necrotic cell death signature for prognostic stratification in pancreatic cancer Vol 17, No 2 (April 30, 2026): Single-nucleus RNA sequencing reveals the effects of key regulators on human pancreatic adenocarcinoma and its tumor microenvironment Vol 17, No 2 (April 30, 2026): Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer Vol 17, No 2 (April 30, 2026): A systematic review of artificial intelligence and machine learning for gut microbiome-based CRC screening Vol 17, No 2 (April 30, 2026): Multimodal data-driven prediction of postoperative recurrence and survival in hepatocellular carcinoma: a narrative review Vol 17, No 2 (April 30, 2026): Risk factors for exclusive lung metastasis in colorectal cancer: a comprehensive narrative review Vol 17, No 2 (April 30, 2026): Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications Vol 17, No 2 (April 30, 2026): A case report of rectal squamous cell carcinoma following radiation therapy for prostate cancer: a management dilemma Vol 17, No 2 (April 30, 2026): Diagnostic challenges in gastrointestinal stromal tumors: a case report of concurrent gastrointestinal stromal tumor, lymphangioma, and solid pseudopapillary neoplasm of the pancreas Vol 17, No 2 (April 30, 2026): Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report Vol 17, No 2 (April 30, 2026): Gastric lymphoma presenting with predominant pancreatitis and cranial neuropathy: a rare clinical presentation—a case report Vol 17, No 2 (April 30, 2026): A case report of gastroesophageal adenocarcinoma with yolk sac tumor differentiation in a pregnant patient Vol 17, No 2 (April 30, 2026): The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers Vol 17, No 2 (April 30, 2026): Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a critical review Vol 17, No 2 (April 30, 2026): Methodological clarifications on maintenance fluoropyrimidines in advanced esophagogastric adenocarcinoma: a real-world Mexican cohort Vol 17, No 2 (April 30, 2026): Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data Vol 17, No 2 (April 30, 2026): Interpreting the evidence base for fruquintinib in refractory metastatic colorectal cancer Vol 17, No 2 (April 30, 2026): Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151 Vol 17, No 2 (April 30, 2026): Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer Vol 17, No 2 (April 30, 2026): Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? —a decade of debate! Vol 17, No 2 (April 30, 2026): Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor Vol 17, No 2 (April 30, 2026): When precision medicine meets human behavior: limits of artificial intelligence in predicting imatinib adherence Vol 17, No 2 (April 30, 2026): Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Muscling in on body surface area to reduce oxaliplatin-induced peripheral neuropathy in colon cancer Vol 17, No 2 (April 30, 2026): Clearing the bar: adding anti-VEGF therapy to chemoimmunotherapy for biliary tract cancer Vol 17, No 2 (April 30, 2026): Maximizing the “toolbox” for patients with initially unresectable colorectal liver metastases: have liver mets “met” their match? Vol 17, No 2 (April 30, 2026): The 12-node rule in irradiated rectal cancer: time for reappraisal? Vol 17, No 2 (April 30, 2026): Beyond drug toxicity: the hidden burden of financial toxicity in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Gastrointestinal malignancies in pregnancy: practical considerations Vol 17, No 2 (April 30, 2026): Intrahepatic cholangiocarcinoma: the equity gap in one of the most lethal cancers Vol 17, No 2 (April 30, 2026): Adjuvant chemotherapy in elderly colon cancer patients: when less may be more Vol 17, No 2 (April 30, 2026): Sarcopenia in esophageal cancer: from passive prognostic marker to active treatment target Vol 17, No 2 (April 30, 2026): Return on investment, return of risk: private equity in gastrointestinal cancer care Vol 17, No 2 (April 30, 2026): Tumor necrosis as a key refinement of risk stratification in gastric gastrointestinal stromal tumors Vol 17, No 2 (April 30, 2026): Survival outcomes in early gastric cancer: evidence from SEER-based population studies Vol 17, No 2 (April 30, 2026): Spontaneous rupture of hepatocellular carcinoma: mechanobiology, rescue, and oncologic control Vol 17, No 2 (April 30, 2026): From waste to wealth: malignant ascites-derived organoids as a compass for precision therapy in advanced gastrointestinal cancers Vol 17, No 2 (April 30, 2026): Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings Vol 17, No 2 (April 30, 2026): Retraction: Interfering HMGB3 release from cancer-associated fibroblasts by miR-200b represses chemoresistance and epithelial-mesenchymal transition of gastric cancer cells Vol 17, No 2 (April 30, 2026): |
Correction: ASO Visual Abstract: Well‑Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes
Fri, 12 Jun 2026 00:00:00 -0700 ASO Visual Abstract: From Clinical Trial Awareness to Practice—Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial Fri, 12 Jun 2026 00:00:00 -0700 High-Intensity Focused Ultrasound Versus Robot-Assisted Radical Prostatectomy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Oncologic and Functional Outcomes Fri, 12 Jun 2026 00:00:00 -0700 ASO Video Abstract: A Stepwise Approach to Laparoscopic Mesohepatectomy: From Complexity to Standardization with Video Demonstration Thu, 11 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Multidisciplinary Tumor Board Documentation—Assessing its Frequency, Quality, and Impact Thu, 11 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study Thu, 11 Jun 2026 00:00:00 -0700 Double Mini Upper Transversal Hepatectomy for Colorectal Liver Metastases Infiltrating the Right and the Left Hepatic Veins at the Hepatocaval Confluence Thu, 11 Jun 2026 00:00:00 -0700 ASO Author Reflections: Robotic Hepatic Artery Infusion Pump Placement in the Era of Robotic Hepatobiliary Surgery: Expanding the Boundaries of a Minimally Invasive Approach in Liver Cancer Treatment Thu, 11 Jun 2026 00:00:00 -0700 Global Curriculum in Surgical Oncology: 2nd Edition, 2026 Thu, 11 Jun 2026 00:00:00 -0700 Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis Using Radiomics: An International Multi-center Cohort Study Thu, 11 Jun 2026 00:00:00 -0700 ASO Author Reflections: Breaking Down Surgical Complexity: A Sequential Framework for Laparoscopic Mesohepatectomy Wed, 10 Jun 2026 00:00:00 -0700 Timing is of the Essence: Why Muscle Mass Trajectories Matter in Patients with Esophageal Squamous Cell Carcinoma Wed, 10 Jun 2026 00:00:00 -0700 Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology Wed, 10 Jun 2026 00:00:00 -0700 Challenges in Managing Primary Retroperitoneal Germ Cell Tumors in Children: The Role of Neoadjuvant Chemotherapy Wed, 10 Jun 2026 00:00:00 -0700 Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance Tue, 09 Jun 2026 00:00:00 -0700 ASO Author Reflection: Are Survival Gains with Neoadjuvant Therapy in Resectable PDAC Real? The Hidden Impact of Immortal Time Bias Tue, 09 Jun 2026 00:00:00 -0700 ASO Author Reflections: When Is the Index Lymph Node Not Enough? Tue, 09 Jun 2026 00:00:00 -0700 ASO Author Reflections: Mortality During the Real-World Adoption of Robotic Pancreaticoduodenectomy in the USA Tue, 09 Jun 2026 00:00:00 -0700 ASO Video Abstract: How to Deal with Median Arcuate Ligament during Pancreaticoduodenectomy? Management Strategies and Impact on Perioperative Outcomes Tue, 09 Jun 2026 00:00:00 -0700 Differential Expression of hsa-miR-34c-5p, hsa-miR-200b-3p, hsa-miR-320a-3p and Their Target Genes Determine Survival in Clear-Cell Renal Cell Carcinoma Tue, 09 Jun 2026 00:00:00 -0700 Cancer Risk After Initial Surveillance of Intraductal Papillary Mucinous Neoplasms (IPMNs): Are We Missing the Window for Prevention? Tue, 09 Jun 2026 00:00:00 -0700 ASO Author Reflections: MicroRNAs and Their Target Genes as a Potential Biomarker and Determine Survival in Clear Cell Renal Cell Carcinoma Mon, 08 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Early Tumor Shrinkage and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study Mon, 08 Jun 2026 00:00:00 -0700 ASO Author Reflections: Expanding the Role of Minimally Invasive Surgery for Retroperitoneal Schwannomas Sun, 07 Jun 2026 00:00:00 -0700 ASO Author Reflections: Beyond Time to Diagnosis: The Lasting Impact of Diagnostic Experience in GIST Sun, 07 Jun 2026 00:00:00 -0700 A Decade Later: An Updated Systematic Review and Meta-analysis of Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple–Areolar Recurrence Following Nipple-Sparing Mastectomy Sun, 07 Jun 2026 00:00:00 -0700 ASO Author Reflections: Beyond Neoadjuvant Therapy in Pancreatic Cancer—Why Adjuvant Therapy Still Matters After Neoadjuvant Treatment Sat, 06 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Increased Mortality with Surgeon Adoption of Robotic Pancreaticoduodenectomy—A National EHR Study of Outcomes Sat, 06 Jun 2026 00:00:00 -0700 Editorial Expression of Concern: Frequent Deletion and Methylation in SH3GL2 and CDKN2A Loci are Associated with Early- and Late-Onset Breast Carcinoma Sat, 06 Jun 2026 00:00:00 -0700 Speaking Volumes About High-Volume Centers Sat, 06 Jun 2026 00:00:00 -0700 Laparoscopic Anatomic Segmentectomy of Segments VIII and IVa with Middle Hepatic Vein Excision Using Ultrasound-Guided ICG Positive Staining Sat, 06 Jun 2026 00:00:00 -0700 Prognostic Significance of the T12-SMI Before and After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma Sat, 06 Jun 2026 00:00:00 -0700 Survival Outcomes in Early Onset Appendiceal Adenocarcinoma (EOAA) Sat, 06 Jun 2026 00:00:00 -0700 Responding to Surgical Errors: From Psychological Impact to Disclosure—A Systematic Review Sat, 06 Jun 2026 00:00:00 -0700 Perforator Versus Non-perforator Flap for Perineal Reconstruction: Long-Term Comparison of Complications and Quality of Life Sat, 06 Jun 2026 00:00:00 -0700 Impact of Concomitant Proton Pump Inhibitor Use on Oncologic Outcomes of Neoadjuvant Chemoimmunotherapy in Locally Advanced Gastric Cancer: A Multicenter Real-World Study Sat, 06 Jun 2026 00:00:00 -0700 Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC): Prospective Cohort with its Nested Randomized Controlled Trial Provides an Example Distinguishing Causation From Association Fri, 05 Jun 2026 00:00:00 -0700 Correction: ASO Author Reflections: It’s Time to Take Dyspepsia Seriously Fri, 05 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response Fri, 05 Jun 2026 00:00:00 -0700 Reply to: Letter to the Editor Concerning “Financial Toxicity Among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study” Fri, 05 Jun 2026 00:00:00 -0700 The Jury Remains Out: The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) Study Highlights the Need for Stringent Trials Investigating the Efficacy of Surgical Intervention Fri, 05 Jun 2026 00:00:00 -0700 Development of a Prediction Model for Skin Graft Failure Following Skin Cancer Excision: The GRAFT Score Fri, 05 Jun 2026 00:00:00 -0700 Association between Surgical Waiting Time and Postoperative Recurrence Risk in Clinical T1bN0M0 Thoracic Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Observational Study Fri, 05 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Differential Expression of hsa-miR-34c-5p, hsa-miR-200b-3p, hsa-miR-320a-3p, and Their Target Genes Determines Survival in Clear Cell Renal Cell Carcinoma Thu, 04 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Utility of 21-Gene Recurrence Score in Male Breast Cancer Thu, 04 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Clinical Course and Risk Factors for Malignant Progression in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata Thu, 04 Jun 2026 00:00:00 -0700 Editorial Expression of Concern: Frequent Alterations of MCPH1 and ATM are Associated with Primary Breast Carcinoma: Clinical and Prognostic Implications Thu, 04 Jun 2026 00:00:00 -0700 Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial Thu, 04 Jun 2026 00:00:00 -0700 Bilateral Wilms Tumor: Looking for the Best Surgical Strategy Thu, 04 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Fluorescence-Guided Remnant-Sparing Laparoscopic Distal Pancreatectomy for Metachronous Pancreatic Cancer Following Whipple Procedure Wed, 03 Jun 2026 00:00:00 -0700 |
||
|
| |||
|
What You May Have Missed in 2025
Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Cardiology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Endocrinology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Gastroenterology/Hepatology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Infectious Diseases: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Nephrology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Oncology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Pulmonology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Rheumatology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID Annals of Internal Medicine, Volume 179, Issue 5, Page 621-628, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia Annals of Internal Medicine, Volume 179, Issue 5, Page 629-636, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey Annals of Internal Medicine, Volume 179, Issue 5, Page 637-644, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Risk Annals of Internal Medicine, Volume 179, Issue 5, Page 645-655, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain Annals of Internal Medicine, Volume 179, Issue 5, Page 656-665, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Functional Status of Adults at Risk of Medicaid Disenrollment Under National Work Requirements Annals of Internal Medicine, Volume 179, Issue 5, Page 666-672, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 673-684, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 685-695, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Prevention of Recurrent Nephrolithiasis in Adults and Children Annals of Internal Medicine, Volume 179, Issue 5, Page 696-707, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Determining the Conclusiveness of Systematic Review Evidence Annals of Internal Medicine, Volume 179, Issue 5, Page 708-720, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 COVID-19 Vaccines for 2025–2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 728-733, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 734-739, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Fostering Support and Inclusion for Physicians, Postgraduate Trainees, and Medical Students With Disabilities: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 721-724, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Improving the Health of and Access to Health Care for People With Disabilities: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 725-727, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Dementia: Clinical Challenges Annals of Internal Medicine, Volume 179, Issue 5, Page 740-741, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Incentivizing Deprescribing for Health Care Quality Not Quantity Annals of Internal Medicine, Volume 179, Issue 5, Page 742-743, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 The Current Threat to the U.S. Preventive Services Task Force and Why It Matters Annals of Internal Medicine, Volume 179, Issue 5, Page 744-745, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.
ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S. Heartseed, World’s First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed CORRECTING and REPLACING Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026) Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer’s Disease Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease |
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.
ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.
Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex and others with similar assets.
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.
Celcuity slides even after ‘practice-changing’ late-stage breast cancer data Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.
ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.
ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results Akeso’s Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Applied Biologics Receives FDA Clearance to Advance BIOxHEAL Into Phase 3 Clinical Development for Diabetic Foot Ulcers Nucala (mepolizumab) approved in Canada for use in adults with chronic obstructive pulmonary disease (COPD) Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in PCED Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment |
Amgen shores up Tavneos’ FDA defense with Duke data analysis
After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.
Portugal, Spain and the new biotech frontier In this episode of Denatured, you’ll be hearing from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc as they discuss the rise of Southern Europe’s biotech ecosystem.
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.
ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.
Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S. Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Heartseed, World’s First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results CORRECTING and REPLACING Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions Akeso’s Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism Airiver Medical Treats First Patient in Pivotal Clinical Study of the Airiver Drug Coated Balloon for Patients with Chronic Rhinosinusitis Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer |
|
|
| |||
|
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:02 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:02 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:02 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:02 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:02 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:02 -0800
|
Identification of mechanism of the oncogenic role of FGFR1 in papillary thyroid carcinoma.
Eur J Histochem. 2024 Jul 22;68(3):4048. doi: 10.4081/ejh.2024.4048. Li XB, Li JL, Wang C, Zhang Y, Li J Mitochondria directly interact with the nuclear pore complex. Nature. 2026 Jun 10. doi: 10.1038/s41586-026-10588-3. Menendez-Montes I, Marin-Vicente C, Mukherjee S, Ahmed MS, Gomez MJ, Anene-Nzelu CG, Lee CJM, Koslowski S, Solmonson A, Tassin T, Ali SR, Pessoa P, Elnwasany A, Lam NT, Thet S, Calvo E, Cardoso AC, Pereira AHM, Xiao F, Wang P, Mohamed A, El-Feky H, Elghamry A, Gancedo-Alonso G, Nguyen NUN, Hsu CC, Westfall AK, DeBerardinis R, Foo RS, Kinter M, Pressé S, Xing C, Szweda L, Aroumougame A, Sanchez-Cabo F, Enriquez JA, Torres M, Vazquez J, Sadek HA Age-related and gender-related differences on hand dexterity in healthy and sports inactive older adults: a cross-sectional study. Z Gerontol Geriatr. 2026 Jan 10. doi: 10.1007/s00391-025-02546-x. Schumacher A, Krumpolt M, Prinz A, Rahil D, Sannemann L, Witte K 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 Jun 9;87(22S):e1889-e2007. doi: 10.1016/j.jacc.2026.03.056. Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, Bajaj M, Bangalore S, Bozkurt B, Breathett K, Clarke SL, de Boer IH, Ellison DH, Evangelista LS, Heffron SP, Kazi DS, Kulshreshtha A, Lingvay I, Low Wang CC, Mercado CA, Morton JM, Neeland IJ, Pagidipati N, Powell-Wiley TM, Rangaswami J, Rao G, Reza N, Saeed A, St Peter W, Starks JB, Sterling M, Talbot AW, Tran AH, Tuttle KR, VanWagner LB, Vest AR, Virani SS 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Jun 9. doi: 10.1161/CIR.0000000000001453. Writing Committee Members; Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, Bajaj M, Bangalore S, Bozkurt B, Breathett K, Clarke SL, de Boer IH, Ellison DH, Evangelista LS, Heffron SP, Kazi DS, Kulshreshtha A, Lingvay I, Low Wang CC, Mercado CA, Morton JM, Neeland IJ, Pagidipati N, Powell-Wiley TM, Rangaswami J, Rao G, Reza N, Saeed A, St Peter W, Starks JB, Sterling M, Talbot AW, Tran AH, Tuttle KR, VanWagner LB, Vest AR, Virani SS Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease. N Engl J Med. 2026 Jun 11;394(22):2212-2222. doi: 10.1056/NEJMoa2513654. Gharahdaghi N, Yeh PJ, Ceron-Gutierrez L, Griffin H, Gordon H, Jayamanne C, Fracchia A, Chong AY, Walsh A, Brain O, Baker K, Kockelbergh H, Luo Y, Guevara Becerra M, Vadakethala K, Coy M, Kabiri L, Barnardo M, Dunachie S, Kronsteiner B, Adams A, Fowler D, Zhang Q, Fachal L, Anderson CA, Desoki R, Vestergaard MV, Larsen L, Wyatt NJ, Lees RD, Mulligan RJ, Dong C, Sharip MT, Faustini SE, Shields A, Pakpoor J, Naz B, Richter A, Satsangi J, Lamb CA, Parkes M, Powrie F, Mentzer AJ, Sazonovs A, Jess T, Klenerman P, Travis S, Hambleton S, Doffinger R, Uhlig HH GPR15-guided CD8+ T regulatory cells control intestinal inflammation. Nature. 2026 Jun 8. doi: 10.1038/s41586-026-10749-4. Cui J, Chen Z, Cheng YH, Nie J, Zhu MH, Xiang C, Chauvin S, Lassoued W, Liu C, Padhan K, Song J, Pai JA, Ocón B, Yang Y, Yao Y, Park AY, Gabrielski JQ, Zheng L, Jiang PD, Zhang Y, Jing H, Xu L, Chen V, Calabresi BA, Pittaluga S, Kleiner DE, Dalgard CL, Sari S, Can S, Karakoc-Aydiner E, Baris S, Erman B, Field M, Silvester JA, Saccocia G, Buhamrah EK, Husain K, Chavoshzadeh Z, Rezaei N, İşlek A, Baş H, Devrez FD, Mackeh R, Fuss IJ, Reich DS, Bailey S, Sater HA, Gulley JL, Kabat J, Smelkinson M, Ganesan S, Chen Z, Grayson PC, Redekar N, Lack J, Lu Z, Lo B, Abolhassani H, Ozen A, Bousvaros A, Snapper SB, Butcher EC, Ravell J, Bosselut R, Su HC, Wu C, Lenardo MJ Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding. Nature. 2026 Jun 8. doi: 10.1038/s41586-026-10738-7. Zeng J, Cheng Z, Chen H, Wang Z, Thompson J, Crosby KT, Han H, Singhal A, Ngo W, Xia C, Rosas-Rivera D, Zhang Z, Kang MH, Mao Y, Diolaiti ME, Lee GC, Diffley JFX, Song Y, Qiu L, Krah NM, Murthy N, Jackson RN, Liu Y, Ashworth A, Doudna JA A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases. Nature. 2026 Jun 10. doi: 10.1038/s41586-026-10633-1. Zang Y, Shi J, Zhao G, Tang B, Liu M, Yao B, Wang G, Pan H, Yang S, Deng R, Zhao Y, Zhang Z, Guo HR, Sun DD, Wang H, Gao L, Yu J, Diao X, Li Y, Li J, Xu HE Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States: We Can No Longer Afford Complacency and Fear. We Must All Act Now! Diabetes Care. 2026 Jun 1;49(6):901-905. doi: 10.2337/dci26-0068. Kahn SE, Anderson CAM, Buse JB, Selvin E Mutation-dependent responses to sleep and exercise in clonal haematopoiesis. Nature. 2026 Jun 10. doi: 10.1038/s41586-026-10634-0. Gerhardt T, Jacob W, Gaebel L, Heiser M, Wolfram C, Huynh P, Nakao T, Gindri Dos Santos B, Toh P, Douglas A, Brisnovali NF, Radkevich E, Uddin MM, Yates AG, Khamhoung A, Yatim N, Gianeselli M, Kiss MG, Goswami S, Nelson D, Chen R, D'Souza D, Chen Z, Kim-Schulze S, Fidler T, Ezzat D, Khurshid S, Bick AG, Natarajan P, Ellinor PT, Rajbhandari AK, Merad M, Swirski FK, Cohen O, Goedeke L, Honigberg MC, McAlpine CS Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nat Metab. 2026 Jun 9. doi: 10.1038/s42255-026-01538-4. Hawkinson TR, Liu Z, Ribas RA, Medina T, Nielsen RS, Clarke HA, Ma X, Mueller AC, Plasencia AF, Sheer AL, Simpson ST, Soto CM, Sudderth J, Cai F, Cantrell AR, Colpaert MG, Shedlock CJ, Wu L, Young LEA, Kooser DD, Chen L, Ryan AM, Quinones S, Son J, Azadi P, Deberardinis RJ, Prokop S, Allison D, Yang S, Chen H, Huang Y, He X, Alonge KM, Guo J, Guo Y, Bian J, Vander Kooi CW, Gentry MS, Sun RC Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer. Nature. 2026 Jun 10. doi: 10.1038/s41586-026-10613-5. Lu X, Wang X, Yang Z, Wang X, Wang L, Xu C, Lo IC, Geng C, Wang L, Pu Y, Zhang K, Zhu Z, Ye L, Huang J, Wei X, Bai F, Zhu Y, Qian X, Dou H, Su H, Cang Y Thioredoxin Reductase 2 Synergizes with Cytochrome c, Somatic to Alleviate Doxorubicin-Induced Oxidative Stress in Cardiomyocytes and Mouse Myocardium. Int Heart J. 2023 Mar 31;64(1):60-70. doi: 10.1536/ihj.22-283. Epub 2023 Jan 31. Li C, Lai H, Cai X, Liu Y, Hong L, Huang X, Shao L Endothelial SHMT2 Drives Pulmonary Vascular Remodeling Through Noncanonical Pathway in Pulmonary Hypertension. Circulation. 2026 Jun 10. doi: 10.1161/CIRCULATIONAHA.125.066183. Wang Q, Tian J, Liu D, Zheng T, Liu X, Zhao Y, Li X, Zhong H, Pan J, Yuan C, Zhao Y, Wang S, Li J, Zhang W, Zhang M, Zhang C, Liu F, Zhang M, Dai S Immersing healthcare students in a virtual reality Parkinson's disease experience. Int J Med Educ. 2024 Mar 29;15:34-36. doi: 10.5116/ijme.65f5.725c. Li YJ, Orlosky J, Jirau-Rosaly W, Brown S, Rockich-Winston N Laparoscopic versus open surgery for suspected appendicitis. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD001546. doi: 10.1002/14651858.CD001546.pub3. Sauerland S, Jaschinski T, Neugebauer EA Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice. Nat Microbiol. 2026 Jun 10. doi: 10.1038/s41564-026-02381-9. Liang X, Zhang Y, Xie W, Xiong J, Lin S, Wen Y, Cao Y, Yu S, Wang K, Deng J, Zhao J, Xu J, Hu Y, Liu Y, Feng Q, Zhong Y, Gonzalez FJ, Xie C Long-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans. Cell. 2026 Jun 10:S0092-8674(26)00589-1. doi: 10.1016/j.cell.2026.05.030. Guo W, Tang H, Yi Z, Zhang T, Yuan P, Wang C, Ren S, Chang X, Ren J, Tang W, Sun W, Liu J, Yu Y, Lu Z, Shen H, Yi Z, Zhao Y, Tang G, Han J, Zhang W, Liu H, Sun X, Zhang Y, Zhang C, Wu Y, Yang L, Han F, Xu Y, Qu L, Sun X, Wang J, Ji W, Chen Y, Wei W Charting human cellular senescence in aging and disease. Cell. 2026 Jun 11;189(12):3501-3505. doi: 10.1016/j.cell.2026.05.028. Suryadevara V, Farzad N, Yang M, Xu K, Tsankov A, Thompson RC, Sloan N, Phatnani H, Olinger B, Mares JA, Lund AN, Li D, Gorospe M, Ding L, Beckmann N, Basisty N, Anerillas C; NIH SenNet consortium; Robbins P, Fan R |
||